Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 31Neoplasms 17Multiple Myeloma 9Thyroid Neoplasms 8Hematologic Neoplasms 7Thyroid Carcinoma, Anaplastic 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Lymphoma 5Glioma 5Colorectal Neoplasms 5Thyroid Cancer, Papillary 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Skin Neoplasms 2Neurofibroma, Plexiform 2Neoplasm Metastasis 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

adavosertib 2veliparib 1trametinib 1spartalizumab 1siltuximab 1pembrolizumab 1Temozolomide 1Specimen Handling 1PT-100 dipeptide 1Magnetic Resonance Spectroscopy 1Everolimus 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Malignant Solid Neoplasm × trametinib × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡